US · ongoing · ~6 min read
Bausch IBS generic-delay claims
2023–present · irritable bowel drugs, generic drugs
Baltimore sued Bausch on September 22, 2026 over an alleged deal to delay a generic IBS drug. An earlier purchaser case dates to 2023. There is no judgment in this file.
The story
The lead purchasers' case was filed in Rhode Island on September 22, 2023.
Baltimore filed a follow-on on the same day three years later.
Pay-for-delay claims accuse a brand and a generic maker of sharing the monopoly period.
Why it matters
Insurers and patients pay the brand price while the generic waits.
What was claimed
Defendants agreed to delay generic competition.
The other side
Patent settlements can be lawful. The complaint has to prove a payment for delay.
What it means for you
A new city complaint does not change the pharmacy price by itself.
Bottom line
The Bausch generic-delay cases are live. A follow-on was filed in September 2026.
Timeline
22 September 2026
Baltimore files
Mayor & City Council of Baltimore v. Bausch Health was filed in Rhode Island, following a September 22, 2023 purchasers' case.
Key dates
- Lead complaint
- 22 September 2023
- Follow-on
- 22 September 2026
Formal snapshot
Summary: Purchasers allege Bausch and others agreed to delay a generic IBS drug. A follow-on complaint was filed September 22, 2026. No judgment is recorded.
Regulator / plaintiff argument: The complaints say a patent settlement or supply deal kept a generic off the market.
Outcome: The September 2026 follow-on shows the dispute is still being filed. This file does not record a liability finding.
Conduct tags
Laws referenced
- Sherman Act §1 — 15 U.S.C. §1
Companies
Reader signals
0 reads · synced via local demo storage — add NEXT_PUBLIC_SUPABASE_* to enable shared likes and comments
Comments
No comments yet — start the thread.